Carey R W, Sohier W D, Kaufman S, Weitzman S A, Kelley R M, Lew R A, Halpern E
Cancer. 1979 Jul;44(1):35-41. doi: 10.1002/1097-0142(197907)44:1<35::aid-cncr2820440107>3.0.co;2-s.
A series of 41 patients at the MGH who received 5-drug chemotherapy, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone, (CMF VP) as adjuvant to surgical treatment of operable breast cancer with 4 or more positive axillary nodes is compared to an analogous group of patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) reported by Bonadonna et al. in an effort to assess the contribution of the treatment program to disease control. The MGH pattern of disease free survival closely parallels that of Bonadonna. Median disease-free survival among the 24 patients who have not recurred is 27 months; among those who recurred 18 months. The analogous medians for treated patients in the Bonadonna study are 24 months and 16 months, as compared to 27 months and 8 months for his nontreated controls. The treatment program, carried out over a two year period, was well tolerated with excellent patient compliance. There was no significant impact, however, in the disease-free survival of postmenopausal patients. While use of this regimen improved disease-free survival in premenopausal individuals, it is clear that a great deal of room for improvement exists, and newer regimens should be investigated.
对麻省总医院（MGH）的41例患者进行了研究，这些患者接受了包含环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、长春新碱和泼尼松的五药化疗方案（CMF VP），作为有4个或更多腋窝淋巴结阳性的可手术乳腺癌手术治疗的辅助治疗，并与Bonadonna等人报道的接受环磷酰胺、甲氨蝶呤和5-氟尿嘧啶（CMF）治疗的类似患者组进行比较，以评估该治疗方案对疾病控制的贡献。MGH的无病生存模式与Bonadonna的模式非常相似。24例未复发患者的无病生存中位数为27个月；复发患者的无病生存中位数为18个月。Bonadonna研究中接受治疗患者的类似中位数分别为24个月和16个月，而其未接受治疗的对照组分别为27个月和8个月。该治疗方案在两年期间实施，耐受性良好，患者依从性极佳。然而，对绝经后患者的无病生存没有显著影响。虽然使用该方案改善了绝经前个体的无病生存，但显然仍有很大的改进空间，应研究更新的方案。
